Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains

The endocannabinoid system is still poorly understood. Recently, the basic elements that constitute it, i.e., membrane receptors, endogenous ligands, and mechanisms for termination of the signaling process, have been partially characterized. There is a considerable lack of information, however, concerning the distribution, concentration, and function of those components in the human body, particularly during pathological events. We have studied the status of some of the components of the endocannabinoid system, fatty acid amide hydrolase and cannabinoid CB1 and CB2 receptors, in postmortem brains from patients with Alzheimer's disease. Using specific polyclonal antibodies, we have performed immunohistochemical analysis in hippocampus and entorhinal cortex sections from brains of Alzheimer's disease patients. Our results show that both fatty acid amide hydrolase and cannabinoid CB2 receptors are abundantly and selectively expressed in neuritic plaque-associated astrocytes and microglia, respectively, whereas the expression of CB1 receptors remains unchanged. In addition, the hydrolase activity seems to be elevated in the plaques and surrounding areas. Thus, some elements of the endocannabinoid system may be postulated as possible modulators of the inflammatory response associated with this neurodegenerative process and as possible targets for new therapeutic approaches.

[1]  K. Mackie,et al.  Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration , 2003, The Journal of Neuroscience.

[2]  P. Zandi,et al.  Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study , 2002, Neurology.

[3]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[4]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Möller,et al.  Astrocytes in Culture Produce Anandamide and Other Acylethanolamides* , 2002, The Journal of Biological Chemistry.

[6]  M. Calero,et al.  Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. , 2002, Brain research. Molecular brain research.

[7]  J. Ramos,et al.  Endocannabinoids and basal ganglia functionality. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[8]  E. Monti,et al.  Endocannabinoids in the immune system and cancer. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[9]  D. Deutsch,et al.  The fatty acid amide hydrolase (FAAH). , 2000, Prostaglandins, leukotrienes, and essential fatty acids.

[10]  Patrick R Hof,et al.  Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer's disease. , 2002, Progress in brain research.

[11]  G. Cabral,et al.  Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. , 2002, International immunopharmacology.

[12]  A. Hofman,et al.  Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. , 2001, The New England journal of medicine.

[13]  D. Piomelli,et al.  Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. , 2001, The Journal of pharmacology and experimental therapeutics.

[14]  C. Breivogel,et al.  Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. , 2001, Molecular pharmacology.

[15]  C. Felder,et al.  The endocannabinoid nervous system: unique opportunities for therapeutic intervention. , 2001, Pharmacology & therapeutics.

[16]  D. Deutsch,et al.  The Cellular Uptake of Anandamide Is Coupled to Its Breakdown by Fatty-acid Amide Hydrolase* , 2001, The Journal of Biological Chemistry.

[17]  R. Strohmeyer,et al.  Molecular and cellular mediators of Alzheimer's disease inflammation. , 2001, Journal of Alzheimer's disease : JAD.

[18]  D. Piomelli,et al.  Carrier‐mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2‐arachidonylglycerol , 2000, Neuroreport.

[19]  D. Giulian Microglia and the immune pathology of Alzheimer disease. , 1999, American journal of human genetics.

[20]  G. Cabral,et al.  The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. , 1999, The Journal of pharmacology and experimental therapeutics.

[21]  K. Mackie,et al.  Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system , 1998, Neuroscience.

[22]  M. Elphick,et al.  A new perspective on cannabinoid signalling: complimentary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. , 1998, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[23]  D. Deutsch,et al.  Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry , 1998, Neuroscience Letters.

[24]  W. Campbell,et al.  Synthesis and characterization of diazomethylarachidonyl ketone: an irreversible inhibitor of N-arachidonylethanolamine amidohydrolase. , 1998, The Journal of pharmacology and experimental therapeutics.

[25]  F. Berrendero,et al.  Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35s]guanylyl-5′-O-(thio)-triphosphate binding in the basal ganglia of aged rats , 1998, Neuroscience.

[26]  J. Sutcliffe,et al.  Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system , 1997, Journal of neuroscience research.

[27]  R. Faull,et al.  Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.

[28]  R. Pertwee Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[29]  A. Buriani,et al.  The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Bisogno,et al.  Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma ‘anandamide amidohydrolase’ , 1995, FEBS letters.

[31]  S. Galiègue,et al.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.

[32]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1990, Neurology.

[33]  M. Herkenham,et al.  Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains , 1994, Neuroscience.

[34]  M. Herkenham,et al.  Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus , 1994, Annals of neurology.

[35]  M. Herkenham,et al.  Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. , 1994, The Journal of pharmacology and experimental therapeutics.

[36]  R. Faull,et al.  Loss of cannabinoid receptors in the substantia nigra in huntington's disease , 1993, Neuroscience.

[37]  J. Vanderhaeghen,et al.  Age-related loss of cannabinoid receptor binding sites and mRNA in the rat striatum , 1992, Neuroscience Letters.

[38]  J. Vanderhaeghen,et al.  Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry , 1992, Neuroscience.

[39]  M. Herkenham,et al.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.